BEIJING, China and BRIDGEWATER, N.J., June 24, 2025 — the American Diabetes Association's 85th Scientific Sessions concluded successfully in Chicago on June 23 (local time). The American Diabetes Association (ADA) Scientific Sessions, hosted by the American Diabetes Association, is the top academic event in the global diabetes field, aiming to share the latest breakthroughs in diabetes diagnosis and treatment. As the world’s leading academic conference in diabetes, the ADA Scientific Sessions convened global experts, researchers, and healthcare professionals to advance cutting-edge developments in diabetes prevention, treatment, and management.

Gan & Lee Pharmaceuticals (Gan & Lee, stock code: 603087.SH), a trailblazer in China’s biopharmaceutical sector, marked its 8th consecutive year at the ADA Scientific Sessions. Gan & Lee presented its innovative diabetes therapeutics, reinforcing its corporate commitment to "Quality First, Innovation Forever."

At this exhibition, Gan & Lee presented multiple phase 2 clinical research results of its self-developed glucagon-like peptide-1 receptor agonist (GLP-1RA) Bofanglutide (GZR18) injection and weekly insulin preparation GZR4 injection in Chinese patients with type 2 diabetes (T2D), and released key data in oral poster form:

In a phase 2a clinical trial, the GLP-1 RA bofanglutide injection demonstrated a favorable safety and tolerability profile after 23 weeks of once-weekly treatment in patients with T2D, with significant HbA1c reductions alongside comprehensive benefits for body weight, blood pressure and blood lipid profiles.

In a phase 2b clinical trial, the bofanglutide injection showed comparable or statistically significant HbA1c and body weight reduction than semaglutide (Ozempic^®) after 24 weeks of bi-weekly treatment in patients with T2D, along with an good safety and tolerability profile.

In a phase 2 clinical trial, the once-weekly insulin GZR4 injection demonstrated comparable efficacy and safety profiles than once-daily insulin degludec (Tresiba^®) in patients with T2D after 16 weeks of treatment. Notably, GZR4 injection achieved statistically significant HbA1c reduction compared to insulin degludec in patients with inadequate glycemic control on basal insulin therapy.

These ultra-long-acting investigational products address critical adherence challenges in conventional therapy through potent glycemic control and reduced injection frequency, positioning them to transform diabetes management paradigms.

In the medical information area of the booth, the company focused on showcasing the latest R&D progress and achievements of the innovative drug bofanglutide and GZR4, and introduced the layout of Gan & Lee’s overseas R&D pipeline. Many authoritative experts in the endocrinology field paid high attention to the unique mechanisms of action of the two drugs, and conducted in-depth exchanges on the differential advantages and clinical application of the drugs.

Dr. Li Zhi, Executive Vice President and Chief Business Officer (CBO) of Gan & Lee Pharmaceuticals, said: “Gan & Lee’s internationalization strategy always takes open cooperation as the core concept, committed to deeply participating in the construction of the global diabetes innovation ecosystem. As an industry benchmark the ADA Scientific Sessions grand event, it provides us with a key platform to demonstrate China's original R&D strength and global layout to the international medical community. We look forward to letting more overseas experts and patients witness Gan & Lee’s innovative breakthroughs and international responsibility through this important event.”

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked  first among all selected companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.